Brentuximab Vedotin

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1816 publications

Vanishing bile duct syndrome in relapsed classic Hodgkin lymphoma: treatment considerations and outcomes.

Vanishing bile duct syndrome in relapsed classic Hodgkin lymphoma: treatment considerations and outcomes.

Journal: BMJ case reports

Published: June 23, 2026

Single-agent gemcitabine enabling successful bridging to allogeneic haematopoietic stem-cell transplantation in refractory peripheral T-cell lymphoma, not otherwise specified.

Single-agent gemcitabine enabling successful bridging to allogeneic haematopoietic stem-cell transplantation in refractory peripheral T-cell lymphoma, not otherwise specified.

Journal: BMJ case reports

Published: June 23, 2026

Diefenbach CS, Jegede O, Wang V, et al. A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma. Blood. 2026;147(18):2041-2052.

Diefenbach CS, Jegede O, Wang V, et al. A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma. Blood. 2026;147(18):2041-2052.

Journal: Blood

Published: June 18, 2026

Microcosting of Childhood Hodgkin Lymphoma Treatment Across Resource Levels Using the Adapted Resource and Implementation Application Guidelines in the US.

Microcosting of Childhood Hodgkin Lymphoma Treatment Across Resource Levels Using the Adapted Resource and Implementation Application Guidelines in the US.

Journal: JCO global oncology

Published: June 10, 2026

Secondary cutaneous involvement in peripheral T-cell lymphoma: Diagnostic frameworks, staging integration, and therapeutic implications.

Secondary cutaneous involvement in peripheral T-cell lymphoma: Diagnostic frameworks, staging integration, and therapeutic implications.

Journal: Journal of investigative medicine : the official publication of the American Federation for Clinical Research

Published: June 02, 2026

Improving salvage regimens prior to autologous stem cell transplantation in relapsed/refractory Hodgkin's lymphoma patients: updates in the novel therapy era.

Improving salvage regimens prior to autologous stem cell transplantation in relapsed/refractory Hodgkin's lymphoma patients: updates in the novel therapy era.

Journal: Expert review of hematology

Published: May 30, 2026

Treatment outcomes of Hodgkin lymphoma in the Czech Republic.

Treatment outcomes of Hodgkin lymphoma in the Czech Republic.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: May 22, 2026

Efficacy and Safety of Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.

Efficacy and Safety of Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.

Journal: Hematological oncology

Published: May 16, 2026

Comparing a treatment combination that includes brentuximab vedotin with standard of care chemotherapy for treating advanced Hodgkin lymphoma: a plain language summary of the HD21 clinical study intended for patients and carers.

Comparing a treatment combination that includes brentuximab vedotin with standard of care chemotherapy for treating advanced Hodgkin lymphoma: a plain language summary of the HD21 clinical study intended for patients and carers.

Journal: Future oncology (London, England)

Published: May 13, 2026

Early Stage Hodgkin Lymphoma-Are We Ready for Novel Agents?

Early Stage Hodgkin Lymphoma-Are We Ready for Novel Agents?

Journal: Clinical lymphoma, myeloma & leukemia

Published: May 07, 2026

Sarcopenia in Patients With Cancer and Its Association With Chemotherapy-Induced Peripheral Neurotoxicity.

Sarcopenia in Patients With Cancer and Its Association With Chemotherapy-Induced Peripheral Neurotoxicity.

Journal: Neurology

Published: May 05, 2026

Innovative approaches for managing relapsed or refractory peripheral T-cell lymphoma.

Innovative approaches for managing relapsed or refractory peripheral T-cell lymphoma.

Journal: Expert opinion on pharmacotherapy

Published: April 28, 2026

Showing 1-12 of 1,816

Last Updated: 06/30/2026